Latest Conference Articles

March 4th 2022, 3:28pm

PER® Miami Breast Cancer Conference

Patients with newly diagnosed metastatic triple-negative breast cancer should undergo PD-L1 expression testing on tumors to determine whether they are candidates for frontline chemoimmunotherapy.

March 4th 2022, 2:30pm

PER® Miami Breast Cancer Conference

Treatment with eribulin elicited an estimated 2-year overall survival rate of 53.6% for patients with metastatic breast cancer previously treated with atezolizumab or sacituzumab govitecan, according to real-world findings.

March 3rd 2022, 3:44pm

PER® Miami Breast Cancer Conference

The 39th Annual Miami Breast Cancer Conference® makes its return to the Fontainebleau Miami Beach in Florida with a twist on both the agenda and the setting.

February 28th 2022, 9:40pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

February 28th 2022, 9:11pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Although checkpoint inhibitors and bispecific antibodies have come to represent clinical oncology’s fourth leg of treatment—immunotherapy—there remains much to explore within lymphoma.

February 28th 2022, 3:00pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The emergence of novel agents, including CAR T-cell therapies and antibody-drug conjugates, plus existing options such as chemoimmunotherapy and bone-marrow transplant, have combined to raise questions about the sequencing of these treatments in patients with diffuse large B-cell lymphoma.

February 20th 2022, 5:40pm

Genitourinary Cancers Symposium (ASCO GU)

The utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.

February 20th 2022, 3:44pm

Genitourinary Cancers Symposium (ASCO GU)

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

February 19th 2022, 9:12pm

Genitourinary Cancers Symposium (ASCO GU)

At a nearly 3-year median follow-up, health-related quality-of-life scores were improved or maintained over time among patients with advanced renal cell carcinoma who received with nivolumab plus cabozantinib compared with those who received sunitinib.

February 19th 2022, 8:38pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of lenvatinib and pembrolizumab produced similar efficacy and safety profiles in an East Asian subgroup of patients with advanced renal cell carcinoma.

February 19th 2022, 8:18pm

Genitourinary Cancers Symposium (ASCO GU)

Efficacy rates generated by the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) vary based on certain immune-cell related parameters in patients with advanced or metastatic clear cell renal cell carcinoma.

February 19th 2022, 8:10pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of nivolumab plus cabozantinib elicited a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma.

February 19th 2022, 7:24pm

Genitourinary Cancers Symposium (ASCO GU)

A reduction in cabozantinib dosage because of toxicity demonstrated improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

February 19th 2022, 6:47pm

Genitourinary Cancers Symposium (ASCO GU)

Follow-up from the TIVO-3 trial showed that patients with pretreated relapsed/refractory renal cell carcinoma who received tivozanib were 5 times more likely to experience long-term progression-free survival compared with sorafenib.

February 19th 2022, 6:30pm

Genitourinary Cancers Symposium (ASCO GU)

Frontline tivozanib was noninferior to other tyrosine kinase inhibitors for the treatment of patients with metastatic renal cell carcinoma in a real-world setting.

February 19th 2022, 5:11pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with lenvatinib plus pembrolizumab was associated with a clinical benefit in advanced renal cell carcinoma, regardless of a patient’s biomarker status.

February 19th 2022, 5:00pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with cabozantinib (Cabometyx, Cometriq) in the second-line setting generated similar time-to-event end points and response rates in patients with advanced renal cell carcinoma, regardless of frontline immune-oncology combinations.

February 19th 2022, 4:50pm

Genitourinary Cancers Symposium (ASCO GU)

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

February 19th 2022, 4:03pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

February 19th 2022, 4:01pm

Genitourinary Cancers Symposium (ASCO GU)

Second-line sacituzumab govitecan plus pembrolizumab generated promising antitumor activity in patients with checkpoint inhibitor–naïve metastatic urothelial cancer.